Kesim Selin, Oksuzoglu Kevser
From the Department of Nuclear Medicine, Marmara University Istanbul Pendik Training and Research Hospital, Istanbul, Turkey.
Clin Nucl Med. 2022 Sep 1;47(9):e585-e586. doi: 10.1097/RLU.0000000000004199. Epub 2022 Apr 5.
A 69-year-old man with a known history of gastric and prostate adenocarcinoma was referred to 68Ga-prostate-specific membrane antigen (PSMA) PET/CT for restaging due to biochemical recurrence of prostate cancer. 68Ga-PSMA PET/CT revealed tracer accumulation in the primary prostatic lesion, lymph node, bone metastases, and brain lesion, which was later confirmed on biopsy to be metastasis of gastric carcinoma. This case reminds us of the variable spectrum of 68Ga-PSMA uptake in prostatic and nonprostatic metastatic lesions, the potential pitfalls on PET/CT images in the workup of patients with concomitant malignancies.
一名69岁男性,有已知的胃腺癌和前列腺腺癌病史,因前列腺癌生化复发而被转诊进行68Ga-前列腺特异性膜抗原(PSMA)PET/CT重新分期。68Ga-PSMA PET/CT显示示踪剂在原发性前列腺病变、淋巴结、骨转移灶和脑病变中积聚,活检后来证实为胃癌转移。该病例提醒我们,68Ga-PSMA在前列腺和非前列腺转移病变中的摄取情况具有多样性,在伴有恶性肿瘤患者的检查中,PET/CT图像存在潜在陷阱。